Shop

A series of Bloomberg stories showed how over-matched and under-resourced regulators at the FDA failed to uncover, trace or stop the spread of cancerous toxins. Even when aware of the problem, the agency was slow to respond and in some cases resistant to warning the public. Delving into the source of these pills, Bloomberg reporters documented how suppliers in China, India and even the U.S. not only cut corners to keep costs down but hid test results that would have shown the consequences of that cost-cutting.